Initially, only a small number of patients and patient groups were able to receive biosimilars. In the past few years more and more indications and active pharmaceutical ingredients were added to the portfolio.
Find out what exactly these are – and why an increasing number of patients is able to receive treatment with biopharmaceuticals thanks to biosimilars here.
